Scientists Have Developed A Cancer-Killing Vaccine And They Are Now Testing It On Humans

Cancer is one of the deadliest diseases known to humanity. It is estimated that about 600,000 people have lost their lives to cancer in the U.S. alone this year.

Luckily, scientists are one step closer to finding a permanent solution to the cancer problem. They believe that they may have finally solved the mystery behind a cancer cure.

Trials are being conducted by scientists at Guy’s Hospital in London, U.K. for developing an unnamed vaccine. The trial should involve 30 patients during the two-year testing phase.

Cancer cancels out the white blood cells that are responsible for fighting diseases and inhibits the immune system once it reaches its advanced stage. This happens when tumor cells damage the immune cells or there’s a decreased number of white blood cells in bone marrow.

The aim of the vaccine is to activate the body’s immune system in destroying cancer cells. The vaccine contains small amounts of antigens, substances that can help spark an immune system response to create antibodies; the researchers hope to be able to counteract the cancers ability to avoid the immune system protection.

These antibodies will be able to destroy tumor cells and retain them for a period of time afterwards to stop any future cases.

Tumor growth and I caused by a small cancer enzyme fragments known as human telomerase reverse transcriptase (hTERT).

The vaccine contains these enzymes in order to stimulate antibodies that specifically target this enzyme and eliminate it. It also contains small doses of chemotherapy in order to speed up the process.

According to scientists, this should be effective for all solid tumors and are now testing its safety on terminal patients who have volunteered.

There’s still a lot to be researched about the vaccine, and any results will be visible in couple of years, but scientists are quite optimistic as it looks very promising.


Leave a Reply

Your email address will not be published. Required fields are marked *